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Abstract
‘Targeted’ or ‘biological’ cancer treatments rely on differential gene expression between normal tissue and cancer, and
genetic changes that render tumour cells especially sensitive to the agent being applied. Problems exist with the
application of many agents as a result of damage to local tissues, tumour evolution and treatment resistance, or
through systemic toxicity. Hence, there is a therapeutic need to uncover specific clinical targets which enhance the
efficacy of cancer treatment whilst minimising the risk to healthy tissues. T-LAK cell-originated protein kinase (TOPK) is
a MAPKK-like kinase which plays a role in cell cycle regulation and mitotic progression. As a consequence, TOPK
expression is minimal in differentiated cells, although its overexpression is a pathophysiological feature of many
tumours. Hence, TOPK has garnered interest as a cancer-specific biomarker and biochemical target with the potential
to enhance cancer therapy whilst causing minimal harm to normal tissues. Small molecule inhibitors of TOPK have
produced encouraging results as a stand-alone treatment in vitro and in vivo, and are expected to advance into
clinical trials in the near future. In this review, we present the current literature pertaining to TOPK as a potential clinical
target and describe the progress made in uncovering its role in tumour development. Firstly, we describe the
functional role of TOPK as a pro-oncogenic kinase, followed by a discussion of its potential as a target for the
treatment of cancers with high-TOPK expression. Next, we provide an overview of the current preclinical progress in
TOPK inhibitor discovery and development, with respect to future adaptation for clinical use.
Facts
● TOPK activity facilitates cell cycle control and
mitotic progression.
● Dysregulated TOPK expression potentiates cancer
development and dissemination.
● High-TOPK expression is tumour-specific and is
associated with poor clinical outcomes.
● TOPK inhibitors have anti-cancer potential when
combined with chemo- or radiotherapy.
Open questions
● What process contributes to dysregulation of TOPK
expression during cancer progression?
● Are there parallels between the function of TOPK in
embryonic stem cells and its behaviour in cancer
stem cells?
● How does TOPK suppression contribute to the
cancer-specific potency of DNA damaging therapies?
● Can TOPK inhibition function as a low risk
alternative to MEK or CDK inhibition in the clinical
treatment of TOPK overexpressing cancers?
Introduction
T-LAK cell-originated protein kinase (TOPK), also
known as PDZ-binding kinase (PBK), is a dual specificity
© The Author(s) 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Katharine J. Herbert (katharine.herbert@oncology.ox.ac.uk)
1CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old
Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
2Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York,
NY, USA
Edited by G. Ciliberto
Official journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
serine/threonine kinase with sequence homology lying
between the phylogenetic branches for MEK1/2 and
MEK7, but with greater functional similarity to the p38-
activating MEKs, MKK3/61. As a member of the dual
specificity family of kinases, it was anticipated that TOPK
would play a role in activation of JNK, ERK and Akt. Early
studies suggested that TOPK facilitates transformation by
upregulating and activating ERK2 through an increase in
AP-1 transcriptional activity2,3. Indeed, a positive feed-
back loop between TOPK and ERK2 was found to amplify
kinase signalling in HCT116 colon cancer cells. In this cell
line, TOPK-mediated pathway activation was indepen-
dent of B-Raf or C-Raf, leading the authors to conclude
that a TOPK/ERK2 feedback loop may be contributing
to transformation potential by bypassing the negative
feedback loop regulating the Raf/MEK/ERK pathway3.
This was later confirmed when TOPK was shown to
activate ERK independently of MEK1/2 as part of the
EGFR signalling pathway, and to contribute to MEK
inhibitor resistance in MCF7 cells4. As a novel regulator
of downstream Raf/MEK/ERK pathway activity, TOPK,
therefore, provides an attractive potential target for che-
motherapeutic inhibitor development.
Localisation, tissue distribution and function
TOPK expression is largely confined to tissues with high
levels of proliferation. Its interest as an oncogenic target
lies in the differential expression of TOPK in multiple
tumour types relative to their normal tissue counter-
parts5–8. Despite this, TOPK knockout does not confer
embryonic lethality in mouse models, with the only phe-
notype reported being an impaired inflammatory response
to UV light exposure in the skin9. TOPK is expressed in
both the nucleus and cytoplasm, however, some reports
indicate that nuclear expression is exclusive to tumour
cells and to those undergoing mitosis6, whilst others do
not detect any difference in localisation10. TOPK mRNA
is detected in several tissue types; and is most abundant
in human tissues derived from testis, placenta and
thymus1,11,12. Of these, the highest signal is measured in
testicular tissue, with expression in this organ confined
exclusively to spermatogenic germ cells in situ13. In brain
tissue, TOPK-expressing cells arise from GFAP-positive
neural progenitor cells in the adult sub-ependymal zone
as well as in the external granule cell layer of the postnatal
cerebellum14. Its expression is exclusive to proliferating
and multipotent neurogenic precursors, and it is sup-
pressed in mature or quiescent neurons.
TOPK expression and phosphorylation consistently
increases as proliferating cells enter mitosis13; and this
process is regulated by Cdk1 in a Cyclin B1-dependent
manner12,15. Although TOPK expression is closely asso-
ciated with Cdk1 during the cell cycle16, the relationship
between Cdk1 and regulation of TOPK phosphorylation is
instead mediated via inactivation of protein phosphatase
1α (PP1α) through the Cyclin B1/Cdk1 complex17. Inac-
tivation of PP1α causes TOPK to become phosphorylated
at Thr9, promoting TOPK activation (Fig. 1). TOPK
activity is primed to peak on entry into prophase, when it
binds to and phosphorylates mitotic C2H2 zinc finger
proteins via its PDZ-binding domain18, and contributes to
chromatin condensation by facilitating phosphorylation of
histone H3 at Ser1019. Thus TOPK activity and expression
contribute to the release of proliferating cells from mid-
mitotic checkpoint control and maintain a timely exit
from mitosis (Fig. 2).
Preclinical rationale: TOPK overexpression in
cancer
High expression of TOPK has been linked to tumour
aggressiveness, invasion and metastatic spread. Indeed,
testing of clinical samples has revealed that a significant
relationship exists between TOPK expression and poor
prognosis in numerous cancers (Table 1). TOPK over-
expression in cancer appears to be facilitated by sup-
pression of microRNA-mediated regulatory control.
Restoration of miR-216b-3p expression in lung cancer cell
lines is sufficient to inhibit proliferation, enhance apop-
totic cell death and overcome TOPK-associated down-
regulation of p53 and p2120.
Development of malignant potential is facilitated by
TOPK-mediated responses to growth and migratory sig-
nalling. An increase in TOPK expression in JB6 epidermal
cells accelerates cell growth and anchorage-independent
colony formation in vitro, as well as promoting tumour
formation in vivo3,21. Conversely, suppression of TOPK
in cancer cell lines inhibits in vivo tumour growth3,21,22. In
addition to its modulating effect on growth and migration,
TOPK promotes epithelial–mesenchymal transition and
facilitates tumour invasiveness. Anchorage-dependent
growth and motility is enhanced by TOPK expression in
prostate and breast cancer cell lines5,6,10,23, and over-
expression of TOPK in metastatic prostate cancer is
Fig. 1 TOPK activity and expression rises at the G2/M border to
facilitate mitotic entry. Activation of TOPK is initiated by Cdk1-
mediated dissociation of protein phosphatase 1 alpha (PP1α). TOPK
activity is instrumental in the stabilisation of the Cdk1/Cyclin B
complex between prophase and metaphase, which promotes spindle
formation and correct chromosomal alignment. Rapid
dephosphorylation of TOPK at the metaphase/anaphase border (mid-
mitotic checkpoint) releases TOPK from Cdk1, enabling proteolytic
degradation of Cyclin B by the anaphase promoting complex (APC). A
drop in Cyclin B levels enables chromosomal migration to spindle
poles and progression into anaphase
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associated with an increase in the expression of matrix
metalloproteinases MMP-2 and -96. These changes were
attributed to nuclear localisation of β-Catenin and acti-
vation of TCF/LEF signalling at gene promotor regions.
Nuclear translocation and activation of β-Catenin sig-
nalling targets MMP-7, Cyclin D1, and TCF-1 is also
enhanced in hepatocellular carcinoma cell lines with
increased TOPK expression, a result supported by clinical
data showing correlation between high-TOPK levels and
nuclear β-Catenin localisation in tissues from hepatocel-
lular carcinoma patients21.
High-throughput screening has raised the possibility of
increased TOPK expression in cancer being representa-
tive of stemness in tumours, however future investigations
are needed to clarify the relationship between TOPK and
proliferation in cancer stem cells (CSC). Nonetheless,
TOPK was ranked fifth in a screen of glioblastoma and
breast cancer cell lines conducted to identify potential
cancer stem cell targets24, and was identified as a marker
for proliferation potential in multipotent stromal cells
derived from bone marrow25. Inhibition of TOPK has
been effective in suppressing growth and survival in CSC
subpopulations of small cell lung cancer cell lines, an
outcome which is thought to be associated with sup-
pression of FOXM1 activity—a key transcription factor
regulating expression of late cell cycle control genes26.
TOPK expression appears to maintain haematopoietic
stem cells in an undifferentiated state, as TOPK inhibition
enhances production of platelets and megakaryocytes
in vivo, and induces myeloid maturation in AML cell lines
by downregulating STAT5 protein expression27,28. Hence,
the interest in TOPK as a potential biomarker for patient
stratification and risk assessment in cancers with high
incidence of acquired treatment resistance and/or
recurrence.
Therapeutic targeting of TOPK
TOPK has demonstrated potential as a therapeutic
target for suppressing cancer development by overcoming
treatment resistance, preventing invasion and metastatic
growth, and promoting cell death signalling in oncogenic
tissues. At a mechanistic level, this appears to occur
through multiple interactions, and in a tumour-specific
manner—predominantly due to the influence of TOPK
overexpression on cancer cell physiology (Table 2).
TOPK promotes tumour dissemination by direct
phosphorylation of p53-related protein kinase (PRPK) at
its Ser250 residue, which in turn regulates the phos-
phorylation status of p53 and Akt. Through this
mechanism, manipulation of TOPK expression in
HCT116 colon cancer xenografts is sufficient to influence
migration and metastatic growth in mouse liver tissue29.
Fig. 2 TOPK activity facilitates mitotic progression. Fluorescent images depict the association between mitotic stage and TOPK activity. Upper
row is stained for TOPK phosphorylated at its Thr9 residue (red). Lower row is stained for proteins bearing the phosphorylated form of the C2H2 zinc
finger consensus linker sequence motif, HpTGEKP (red). Phosphorylation at this motif coordinates the dissociation of C2H2 zinc finger proteins (ZFP)
from condensed chromatin, enabling mitotic progression56. TOPK has been identified as the primary kinase responsible for phosphorylation of
HpTGEKP bearing proteins during mitosis18. Tubulin is counterstained green, and DNA is identified by DAPI staining (blue)
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Relative expression of TOPK and its downstream target,
PRPK, are also related to metastatic potential in colorectal
carcinoma and squamous cell carcinoma30,31. Further,
TOPK knockout mice are resistant to solar stimulated
light-induced skin cancer31. For patients with acute
myeloid leukaemia (AML), myeloid maturation in FTL3-
ITD positive AML cells appears to be partially suppressed
by a feedback loop between TOPK and the transcription
factor responsible for granulocyte differentiation, CEBPA.
In CD34 positive myeloblasts, inhibition of TOPK in
FTL3-ITD positive AML promotes apoptotic cell death
and increased myeloid differentiation28.
TOPK activation increases during oxidative stress, and
provides protection to cells in pro-inflammatory envir-
onments when overexpressed. TOPK-mediated phos-
phorylation of γH2AX and peroxiredoxin 1 significantly
suppresses induction of apoptotic signalling cascades in
melanoma cell lines, conferring resistance to arsenite-
induced and UVB-induced apoptotic cell death32,33.
Overexpression of TOPK was also found to provide
protection against myocardial and neuronal ischaemia-
reperfusion injury by enhancing activation of the Akt
signalling pathway and by upregulating expression of
antioxidative proteins34,35. In both these investigations,
inhibition of TOPK reduced cell viability and aggravated
ischaemia-induced injury in vitro and in vivo.
Combination TOPK targeting in cancer therapy regi-
mens has the potential to enhance treatment efficacy
when coupled with DNA damaging agents. Suppression of
TOPK activity proportionately increases the apoptotic
fraction of tumour cells by upregulating pro-apoptotic
p53 transcriptional targets, NOXA, BAK, FAS and Caspase
10 28, downregulating Bcl-XL expression36 and increasing
PARP and caspase 3 cleavage via JNK and p38 signal
pathway activation22. TOPK also confers resistance to
TRAIL-induced apoptotic cell death37, which, along with
IκBα phosphorylation and RelA nuclear translocation38,
link TOPK activity to aberrant NF-κB signalling and
cancer progression. An increase in polyploidy following
doxorubicin treatment indicates that mitosis occurs
aberrantly for TOPK overexpressing cells as a response to
damaged DNA39. Indeed, TOPK knockdown or inhibition
enhances radiation sensitivity in a tumour-specific man-
ner by impeding resolution of DNA damage and
increasing apoptotic cell death40. Taken together,
increased TOPK expression in cancer cells promotes the
Table 2 TOPK is a pro-oncogenic kinase with chemotherapeutic potential
Characteristic Mechanism References
Tumour dissemination PRPK phosphorylation (Ser250) by TOPK regulates p53- and Akt-mediated activation of tumour cell
migration and invasion.
29
Proliferative potential,
replicative immortality
TOPK expression is regulated by a negative feedback loop via FLT3 expression and CEBPA phosphorylation. 28
Apoptotic resistance TOPK binds histone H2A, promoting nuclear colocalisation and phosphorylation of γH2AX. 32
TOPK and PRX1 colocalise in the nucleus. TOPK regulates PRX1 peroxidase activity by phosphorylation
at Ser32.
33
Cell death signalling TOPK suppresses p53-mediated transcription of pro-apoptotic intermediates in tumour cells. 28,36
TOPK confers resistance to TRAIL-induced apoptotic cell death via NF-κB mediated transcriptional activity. 37
TOPK directly phosphorylates IκBα at Ser-32 and promotes RelA nuclear translocation. Overexpression
enhances NF-κB and cIAP2 transcriptional activity.
38
Oxidative damage TOPK activation protects against cell death by enhancing the Bcl-2/Bax ratio. 34
pAkt and pTOPK colocalise in neural cells following ischaemia, increasing expression of peroxiredoxins-1 and
2, and thioredoxin-1.
35
TOPK suppresses JNK/p38 signal pathway activation during exposure to oxidising conditions. 22
DNA damage TOPK expression in cancer cell lines promotes resolution of chromosomal errors following DNA damage. 40
TOPK expression is regulated by E2F and CREB/ATF-mediated transcription. TOPK directly interacts with p53
and promotes molecular destabilisation.
39
Increased TOPK expression in cancer cells promotes the activation of multiple pathways involved in sustained growth and proliferation, evasion of cell death, invasive
potential and metastatic growth. Inhibition of TOPK activity restores cellular responses to cell death signalling and replicative control mechanisms, as well as
overcoming oncogenic chemoresistance by sensitising cancer cells to DNA damaging agents.
Key: TOPK T-LAK cell-originated protein kinase, FLT3 fms-like tyrosine kinase 3 (CD135), CEBPA CCAAT/enhancer-binding protein alpha, NF-κB nuclear factor kappa light
chain enhancer of activated B cells, TRAIL TNF-related apoptosis-inducing ligand, IκBα inhibitor of kappa B, CREB/ATF cAMP response element binding protein
activating transcription factor, PRPK p53-related protein kinase, PRX1 Peroxiredoxin 1.
Herbert et al. Cell Death and Disease          (2018) 9:1089 Page 5 of 10
Official journal of the Cell Death Differentiation Association
activation of multiple signalling pathways involved in
reinforcing the hallmarks of cancer. Thus TOPK repre-
sents a master regulatory kinase whose manipulation has
the potential to disrupt pro-carcinogenic processes, sup-
port the efficacy of DNA damaging agents and to over-
come chemoresistance during cancer treatment.
Development of TOPK inhibitors
Three inhibitors have been developed to specifically
target TOPK: HI-TOPK-032;41 OTS514/OTS964;27 and
ADA-0742 (Table 3). The first of these, HI-TOPK-032,
suppressed proliferation of colon cancer cells in vitro and
partially suppressed colorectal and nasopharyngeal
xenograft growth in vivo22,43. More recently, ADA-07
showed potential as a chemopreventive and therapeutic
agent in the treatment of skin cancer. Inhibition of TOPK
by topical application of ADA-07 suppressed develop-
ment of solar ultraviolet-induced tumour development in
mouse skin following exposure to solar irradiation42.
Two novel high potency compounds (OTS514 and its
methylated derivative, OTS964) effectively inhibit lung
tumour growth in murine xenografts when delivered by
either oral or intravenous routes27. TOPK inhibition with
OTS964 or OTS514 abolished ex vivo growth of patient-
derived ovarian cancer cells in a dose-dependent manner,
and completely suppressed dissemination of ovarian
malignancy in peritoneal xenografts44, although free
OTS964 and OTS514 triggered significant weight loss and
haematological toxicity during administration. Liposomal
delivery was then adopted to improve tumour-specific
uptake through the enhanced permeation and retention
effect. This strategy prevented anaemia and leukocyto-
penia associated with intravenous treatment from devel-
oping, and enabled full recovery following oral delivery of
the compounds. More recently, 18F-labelled OTS964 has
shown favourable pharmacokinetics and biodistribution
when injected intravenously in a glioblastoma-carrying
mouse model45. Preclinical validation of [18F]FE-OTS964
is a promising first step towards the future use of TOPK
inhibitors in a clinical context by enabling PET imaging of
TOPK positive tumours.
Investigations into the mechanistic potential for tumour
growth suppression by OTS514 in TOPK-expressing
tumour cell lines have found that dose-dependent
growth suppression and increased apoptotic cell death is
associated with a reduction in FOXM1 activity and down-
regulation of TOPK and MELK expression8,26. These
studies hint at a role for TOPK in stem cell differentiation
through regulation of FOXM1-mediated transcriptional
activity and MELK signalling. Indeed, whilst in vivo
administration of OTS514 causes leukocytopenia, it con-
currently increases the megakaryocyte subpopulation and
peripheral platelets in treated mice, indicating that dif-
ferentiation of haematopoietic stem cells is altered by Ta
b
le
3
C
h
ar
ac
te
ri
sa
ti
on
of
TO
PK
in
h
ib
it
or
s—
p
re
cl
in
ic
al
st
ud
ie
s
In
hi
b
it
or
M
od
el
Se
ns
it
iv
it
y
Sp
ec
ifi
ct
y
Re
fe
re
nc
es
H
I-T
O
PK
-0
32
Ki
na
se
ac
tiv
ity
[%
In
hi
bi
tio
n]
TO
PK
(6
0%
)
[2
μ
M
H
I-T
O
PK
-3
2]
O
th
er
ki
na
se
ta
rg
et
s:
M
EK
1
(2
0%
),
ER
K1
(0
%
),
JN
K1
(0
%
),
p3
8
(0
%
)
41
C
ol
on
ca
nc
er
ce
ll
lin
es
na
so
ph
ar
yn
ge
al
ca
rc
in
om
a
ce
ll
lin
es
0.
5–
5
μ
M
,1
0
μ
M
↓
G
ro
w
th
,↓
A
nc
ho
ra
ge
-in
de
pe
nd
en
t
co
lo
ny
fo
rm
at
io
n
22
,4
1
0.
5–
8
μ
M
↑
D
N
A
fra
gm
en
ta
tio
n
an
d
ce
ll
de
at
h,
↑
In
tr
ac
el
lu
la
r
RO
S
43
s.c
.x
en
og
ra
ft
H
C
T-
11
6
[1
0
m
g/
kg
t.i
.w
.(
25
da
ys
)]
C
N
F-
2
[5
m
g/
kg
t.i
.w
.(
14
da
ys
)]
H
T-
29
[5
m
g/
kg
t.i
.w
.(
20
da
ys
)]
↓
Tu
m
ou
r
gr
ow
th
,N
o
w
ei
gh
t
lo
ss
↓
Tu
m
ou
r
gr
ow
th
,N
o
w
ei
gh
t
lo
ss
C
he
m
os
en
si
tis
at
io
n
(o
xa
lip
la
tin
)
41
A
D
A
-0
7
Ki
na
se
as
sa
y
N
H
D
F,
A
43
1
&
SC
C
12
JB
6
P
+
In
hi
bi
tio
n
[5
-1
0
μ
M
A
D
A
-0
7]
0.
62
5-
10
μ
M
1.
25
-1
0
μ
M
C
o-
pr
ec
ip
ita
tio
n,
no
M
EK
1
in
hi
bi
tio
n
↓
G
ro
w
th
,↓
A
nc
ho
ra
ge
-d
ep
en
de
nt
co
lo
ny
fo
rm
at
io
n
↓
Tr
an
sf
or
m
at
io
n
po
te
nt
ia
l
42
SU
V-
in
du
ce
d
pa
pi
llo
m
a
fo
rm
at
io
n
[0
.1
m
g,
1
m
g
(t
op
ic
al
)
t.i
.w
.(
28
w
ee
ks
)]
↓
Tu
m
or
ig
en
es
is
(e
ar
ly
-s
ta
ge
),
↓
Pa
pi
llo
m
a
fo
rm
at
io
n
(la
te
-s
ta
ge
)
N
o
cy
to
to
xi
ci
ty
42
Herbert et al. Cell Death and Disease          (2018) 9:1089 Page 6 of 10
Official journal of the Cell Death Differentiation Association
Ta
b
le
3
co
nt
in
ue
d
In
hi
b
it
or
M
od
el
Se
ns
it
iv
it
y
Sp
ec
ifi
ct
y
Re
fe
re
nc
es
O
TS
51
4
Ki
na
se
ac
tiv
ity
[%
In
hi
bi
tio
n]
TO
PK
(8
4%
)
[0
.2
μ
M
O
TS
51
4]
O
th
er
ki
na
se
ta
rg
et
s:
cS
rc
(6
1%
),
FL
T3
(4
4%
),
FY
N
(1
9%
),
LY
N
(2
8%
),
C
D
K2
/C
yc
lin
A
(6
0%
),
BT
K
(1
2%
),
D
A
PK
1
(2
9%
),
G
SK
3b
(2
5%
),
IG
F1
R
(2
8%
),
IR
A
K4
(2
1%
),
RE
T
(1
3%
),
TA
K1
(4
2%
)
27
SC
LC
ce
ll
lin
es
,K
id
ne
y
ca
nc
er
ce
ll
lin
es
,O
va
ria
n
ca
nc
er
ce
ll
lin
es
IC
50
va
lu
es
:D
M
S1
14
(1
.3
nM
),
H
69
A
R
(7
.3
nM
),
H
44
6
(8
.4
nM
),
H
69
(0
.4
nM
),
H
82
(7
.2
nM
),
H
14
6
(3
9.
3
nM
),
H
52
4
(2
.6
nM
),
H
21
71
(4
2.
6
nM
),
D
M
S2
73
(4
.1
nM
),
SB
C
-3
(2
.0
nM
),
SB
C
-5
(3
.7
nM
),
VM
RC
-R
C
W
(1
9.
9
nM
),
C
ak
i-1
(2
7.
8
nM
),
Ca
ki
-2
(2
0.
1
nM
),
76
9-
P
(2
0.
7
nM
),
78
6-
O
(4
4.
1
nM
),
C
aO
V3
(3
nM
),
O
VT
O
KO
(4
6
nM
).
↓
G
ro
w
th
,↑
ap
op
to
tic
ce
ll
de
at
h
Se
ns
iti
vi
ty
is
re
la
tiv
e
to
in
tr
in
si
c
TO
PK
ex
pr
es
si
on
↓
FO
XM
1
tr
an
sc
rip
tio
n
↓
TO
PK
pr
ot
ei
n
ex
pr
es
si
on
8,
26
,4
4
s.c
.x
en
og
ra
ft
A
54
9,
LU
-9
9
[1
,2
.5
,5
m
g/
kg
t.i
.w
.(
14
da
ys
)]
↓
Tu
m
ou
r
gr
ow
th
,H
ae
m
at
op
oi
et
ic
to
xi
ci
ty
(fr
ee
);
sl
ig
ht
re
du
ct
io
n
in
bo
dy
w
ei
gh
t
(li
po
so
m
al
,h
ig
h
do
se
)
27
M
et
as
ta
tic
gr
ow
th
[2
5
m
g/
kg
,q
.d
.(
14
da
ys
)
50
m
g/
kg
,q
.d
.(
11
da
ys
)]
A
bo
lit
io
n
of
tu
m
ou
r
gr
ow
th
in
15
%
>
20
%
w
ei
gh
t
lo
ss
in
hi
gh
do
se
gr
ou
p
↓
G
ro
w
th
,S
en
si
tiv
ity
do
es
no
t
va
ry
ac
co
rd
in
g
to
tu
m
ou
r
si
te
or
hi
st
ol
og
ic
al
ty
pe
44
Ex
vi
vo
(p
at
ie
nt
de
riv
ed
)
O
va
ria
n
ca
nc
er
(1
0
nM
,1
00
nM
)
O
TS
96
4
Ki
na
se
ac
tiv
ity
[%
In
hi
bi
tio
n]
TO
PK
(8
0%
)
[2
μ
M
O
TS
96
4]
O
th
er
ki
na
se
ta
rg
et
s:
cS
rc
(8
8%
),
FL
T3
(7
2%
),
FY
N
(6
3%
),
LY
N
(7
7%
),
M
EL
K
(6
1%
),
C
D
K2
/C
yc
lin
A
(4
4%
),
BT
K
(5
2%
),
D
A
PK
1
(4
2%
),
G
SK
3b
(4
5%
),
IG
F1
R
(4
0%
),
IR
A
K4
(4
3%
),
PI
M
1
(5
9%
),
RE
T
(4
1%
),
TA
K1
(4
4%
)
27
Va
rio
us
ca
nc
er
ce
ll
lin
es
IC
50
va
lu
es
:A
54
9
(3
1
nM
),
LU
99
(7
.6
nM
),
D
U
44
75
(5
3
nM
),
M
D
A
-M
B-
23
1
(7
3
nM
),
T4
7D
(7
2
nM
),
D
au
di
(2
5
nM
),
U
M
-U
C
-3
(3
2
nM
),
H
C
T-
11
6
(3
3
nM
),
H
T2
9
(2
90
nM
),
M
KN
1
(3
8
nM
),
M
KN
45
(3
9
nM
),
H
ep
G
2
(1
9
nM
),
M
IA
Pa
ca
-2
(3
0
nM
),
22
Rv
1
(5
0
nM
),
C
aO
V3
(1
4
nM
),
RM
G
-1
(1
10
nM
),
H
el
a
(6
0
nM
),
M
RC
5
(1
85
nM
),
H
FL
-1
(1
75
nM
),
D
U
14
5
(4
3
nM
),
PC
3
(1
47
nM
),
H
12
99
(8
8
nM
),
T2
4
(1
53
nM
),
SQ
20
B
(5
9
nM
),
H
A
P1
(8
3
nM
).
↓
G
ro
w
th
,↑
ap
op
to
tic
ce
ll
de
at
h
Se
ns
iti
vi
ty
is
tu
m
ou
r
ce
ll
lin
e-
sp
ec
ifi
c,
tu
m
ou
r-
sp
ec
ifi
c
ra
di
os
en
si
tis
at
io
n
27
,4
0
s.c
.x
en
og
ra
ft
LU
-9
9
[4
0
m
g/
kg
i.v
.(
×
6
in
18
da
ys
)
50
or
10
0
m
g/
kg
p.
o.
]
↓
Tu
m
ou
r
gr
ow
th
w
ith
co
m
pl
et
e
re
gr
es
si
on
,
tr
an
si
en
t
ha
em
at
op
oi
et
ic
to
xi
ci
ty
27
Ke
y:
RO
S
re
ac
tiv
e
ox
yg
en
sp
ec
ie
s,
s.
c.
su
bc
ut
an
eo
us
,i
.v
.i
nt
ra
ve
no
us
,t
.i.
w
.t
hr
ee
tim
es
pe
r
w
ee
k,
SU
V
so
la
r
ul
tr
av
io
le
t
ra
di
at
io
n,
SC
LC
sm
al
l
ce
ll
lu
ng
ca
nc
er
,q
.d
.d
ai
ly
,p
.o
.o
ra
l
do
si
ng
Herbert et al. Cell Death and Disease          (2018) 9:1089 Page 7 of 10
Official journal of the Cell Death Differentiation Association
TOPK inhibition27. Furthermore, in vitro exposure to
OTS964 decreases the CSC subpopulation in CD56
positive small cell lung cancer cell lines26.
Conclusions and future directions
Current therapeutic strategies to interfere with the
proliferative potential of cancer involve either inhibition of
mitogenic activating factors, or manipulation of cell cycle
regulatory proteins. Of the mitogenic activators, dual
specificity MEK homologues are highly prised potential
targets for tackling cancers with dysregulated EGFR, Ras
or Raf activity46,47. The small molecule inhibitors of
MEK1/2 developed to date are highly potent and selective
for the MEK-ERK pathway, however, systemic toxicity and
acquired resistance have been limiting factors in clinical
development48. The most promising regulatory targets are
cyclin-dependent kinases (CDKs) (most recently CDK4/
6 selective inhibitors) and checkpoint kinases (particularly
WEE1, CHK1 and PLK inhibitors). However, despite
demonstrating high potency in preclinical studies, early
clinical trials with first and second-generation pan-CDK
inhibitors have been disappointing. More highly selective
CDK4/6 inhibitors have produced more encouraging
outcomes, although dosing is limited by neutropoenia, and
efficacy is modest when these inhibitors are used as single
agents49,50. It appears that in order to maximise cancer
treatment strategies in the future, a range of potential
options will be required in the clinician’s arsenal to per-
sonalise combination therapies and to combat refractory
resistance. As an emerging alternative to the current cell
cycle regulatory targets described above, TOPK’s che-
motherapeutic potential is threefold:
(1) TOPK expression is enhanced in tumours arising
from numerous histological subtypes and is
suppressed in non-transformed cells from
differentiated tissues. Dysregulation of TOPK
appears to promote tumour growth and
progression by enabling cancer cells to overcome
cell death signalling pathways, bypass regulatory
checkpoint control mechanisms and migrate
beyond their point of origin. Hence, inhibition of
TOPK is an attractive biochemical strategy for
overcoming tumour aggression, metastatic growth
and therapeutic resistance.
(2) Expression in untransformed tissues is relatively
low and appears to be non-essential to development
or cellular function. TOPK activity rises during the
progression towards mitosis and peaks in prophase,
however evidence suggests that it is functionally
redundant for cell division. Cells with TOPK
knockdown continue to undergo growth and
proliferation in vitro, and TOPK knockout mice are
healthy, unlike MEK1−/− mice, which are non-
viable51. Consequently, TOPK inhibition is less
likely to be associated with normal tissue toxicity
compared to existing MEK1/2 and CDK inhibitors.
(3) TOPK facilitates the fidelity and duration of mitosis
in actively dividing tissues, predominantly via its
influence over checkpoint control proteins.
Enhanced expression of TOPK supports the
demands of increased proliferative activity in
carcinogenic tissue by optimising mitotic efficiency.
Equally, suppression of TOPK activity weakens the
regulatory efficacy of mid-mitotic signalling, with
the potential to elongate the transition between
prophase and anaphase and either stall, or delay,
mitotic progression. Mitotic defects facilitate
tumorigenesis52, however, complete disabling of
mitotic checkpoint control has been proposed as a
potential anticancer strategy53–55.
Adaptation to TOPK-mediated signalling by cancer cells
creates a dependence on TOPK for mitotic checkpoint
control which can be exploited by chemotherapeutic
inhibition in combination with DNA damaging agents. As
yet, development of pharmaceutical strategies for targeting
TOPK overexpression in cancer patients remain in the
preclinical stage, and sensitivity and specificity for the
majority of compounds developed to date is low. Of
the possibilities outlined in this review, OTS514 and
OTS964 are the only compounds which inhibit TOPK
activity with high potency, however, these agents are
particularly non-specific, with co-inhibition of other
kinases demonstrated to various degrees in either case27.
Both of these compounds have been associated with hae-
matological toxicity in vivo, and therefore it is highly likely
that their mechanism of action involves indirect targeting
of multiple kinases, so their effect on tumour growth may
be combinatorial. Nonetheless, novel MEK family mem-
bers, such as TOPK, represent druggable targets of dys-
regulated signalling pathways with the potential to bypass
the adverse outcomes posed by MEK1/2-targeting inhibi-
tors. As single agents or in combination with therapeutics,
selective TOPK inhibitors have the capacity to potentiate
the impact of DNA damaging agents by abrogating cell
cycle checkpoint control and by re-establishing pro-
apoptotic signalling in resistant tumours.
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